STOCK TITAN
  1. Home
  2. Sec-filings
  3. TEVA
  4. [Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Teva (NYSE: TEVA) director converts 14,492 RSUs into ordinary shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares. The units were granted on June 5, 2025 and vested on June 5, 2026, and each unit settled into one ordinary share at no cash cost to him.

The ordinary shares may be held directly or represented by American Depositary Shares, each currently equal to one ordinary share. The filing reflects a compensation-related equity vesting and exercise, not an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Lichtenstein Chen
Role null
Type Security Shares Price Value
Exercise Restricted Share Units 14,492 $0.00 --
Exercise Ordinary Shares 14,492 $0.00 --
Holdings After Transaction: Restricted Share Units — 0 shares (Direct, null); Ordinary Shares — 19,296 shares (Direct, null)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
RSUs exercised 14,492 units Restricted share units converted to ordinary shares on June 5, 2026
Shares held after transaction 19,296 shares Direct ordinary share holdings following RSU exercise
Exercise price per RSU $0.00 per unit Settlement of restricted share units into ordinary shares
Derivative exercises in filing 1 transaction, 14,492 shares Transaction code M, exercise or conversion of derivative security
ADS to ordinary share ratio 1 ADS : 1 share Each American Depositary Share represents one ordinary share
RSU grant date June 5, 2025 Grant date of restricted share units later exercised
RSU vesting date June 5, 2026 Vesting date triggering settlement into ordinary shares
Restricted Share Units financial
"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or cash."
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Exercise or conversion of derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security."
contingent right financial
"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or the cash value."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lichtenstein Chen
(Last)(First)(Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
(Street)
TEL AVIVISRAEL6944020
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)06/05/2026M14,492A(2)19,296D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Share Units(2)06/05/2026M14,492 (3) (3)Ordinary Shares(1)14,492$00D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
/s/ Dov Bergwerk as attorney-in-fact for Chen Lichtenstein06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Teva (TEVA) director Chen Lichtenstein report?

Chen Lichtenstein reported exercising 14,492 restricted share units into ordinary shares. This converted previously granted equity awards into shares he now holds directly, without an open-market purchase or sale involved in the transaction.

How many Teva (TEVA) shares does Chen Lichtenstein hold after this Form 4?

After the reported exercise, Chen Lichtenstein holds 19,296 ordinary shares directly. This figure reflects the addition of 14,492 shares from vested restricted share units that settled into ordinary shares on June 5, 2026.

What does the 14,492-share transaction in Teva (TEVA) represent?

The 14,492 shares represent restricted share units that vested and were exercised into ordinary shares. Each unit settled into one share at a stated price of $0.00, indicating a compensation-related equity grant rather than a market purchase.

Were Teva (TEVA) shares bought or sold on the market in this Form 4?

No open-market buying or selling occurred. The Form 4 shows a derivative exercise of 14,492 restricted share units into ordinary shares, a routine conversion of vested equity awards rather than a discretionary market trade.

When did the Teva (TEVA) restricted share units reported by Chen Lichtenstein vest?

The restricted share units were granted on June 5, 2025 and vested on June 5, 2026. Upon vesting, 14,492 units converted into an equal number of ordinary shares in this compensation-related transaction.